Portal de investigación
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Paz-Ares, Luis G.
- Spigel, David R.
- Chen, Yuanbin
- Jove, Maria
- Rich, Patricia
- Hayes, Theresa M.
- Calderon, M. Vanesa Gutierrez
- Caro, Reyes Bernabe
- Navarro, Alejandro
- Dowlati, Afshin
- Zhang, Bin
- Moore, Yan
- Wang, Haofei Tiffany
- Kokhreidze, Jaba
- Aix, Santiago Ponce
- Bunn, Paul
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Paz,LG,Spigel,DR,Chen,Y,Jove,M,Juan,O,Rich,P,Hayes,TM et al. RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2020. ELECTR NETWORK-MAY 29-31. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2020.